GlassScriptPhysician profile
Alyssa A Naylor
NPI 1679140057
$1,240.87
in general payments reported to CMS, 2019-2025
13 companies · $421 in 2025
The $421 reported for 2025 was more than what 83% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $379 · 2024: $441 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,240.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $378.20 | 2023-2025 | |
| Astellas Pharma US INC | $216.79 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $144.77 | 2023-2025 | |
| Shield Therapeutics INC | $135.43 | 2023-2025 | Accrufer |
| Pfizer INC. | $101.35 | 2023-2025 | |
| Abbvie INC. | $89.31 | 2023 | |
| Novo Nordisk INC | $56.43 | 2023-2025 | Wegovy |
| Organon LLC | $30.30 | 2024 | |
| Coopersurgical, INC. | $22.23 | 2024 | Paragard T 380a |
| Lilly USA, LLC | $21.12 | 2024 | Zepbound |
| Sumitomo Pharma America, INC. | $16.76 | 2025 | Myfembree |
| Biogen, INC. | $15.28 | 2025 | Zurzuvae |
| Olympus America INC. | $12.90 | 2023 | Olympus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Naylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.